Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $4
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum maintains a Buy rating on Selecta Biosciences (NASDAQ:SELB) but lowers the price target from $5 to $4.
August 18, 2023 | 8:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a Buy rating on Selecta Biosciences but lowers the price target from $5 to $4.
The news is directly related to Selecta Biosciences (SELB). While the maintained Buy rating is positive, the lowered price target from $5 to $4 might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100